Pharmaka provides end-to-end site activation for psychedelic clinical trials. Every engagement is structured around a fixed scope, defined milestones, and clear expectations - for both the site and Pharmaka.
Each workstream is scoped, priced, and sequenced against the actual critical path of a site activation. You always know what phase you’re in and what happens next.
Assessment of your site’s current readiness for psychedelic Phase II and III trials. Active outreach to sponsors on your behalf. Representation in feasibility conversations and site evaluation visits.
Preparation and submission support for Schedule I controlled substance licensure. Guidance on physical security requirements, controlled substance storage compliance, and inspection readiness.
Development of standard operating procedures for drug handling, dosing rooms, and patient monitoring - built to hold up under sponsor and regulator review.
Training for principal investigators, coordinators, and clinical staff on psychedelic clinical trial protocols. Guidance on facilitator recruitment and credentialing, including the mental-health credential requirements for lead and assistant facilitators.
Pre-audit dry runs, documentation review, and preparation for sponsor site evaluation visits. Real-time support during on-site visits.
Retainer plus milestone-based pricing. Pharmaka works toward getting your site onboarded to at least one psychedelic study, with a study contingency clause that protects both parties if a qualifying study cannot be sourced.
Every activation runs as one coordinated engagement with two components. A fixed monthly retainer covers the continuous work - sponsor outreach, regulatory strategy, SOP development, and staff guidance - across the life of the engagement. Alongside it, milestone payments are tied to specific, verifiable events, so a meaningful share of the fee is earned only as your site actually advances.
Three milestones anchor that structure:
Because those milestones are real regulatory and sponsor events, you’re paying against progress rather than billable hours. Scope, timeline, and structure are set in writing at the start and adjust only by mutual agreement, and a study contingency clause protects both parties if a qualifying study cannot be sourced. Exact figures are walked through on our first call.
There are important things Pharmaka does not do. Being clear about them protects the quality of the work we do deliver, and gives you a truthful picture of what we can and cannot control.
Pharmaka also works with clinical research site networks. Multi-site engagements offer tiered volume pricing and include network-level advisory on regulatory strategy, sponsor business development, and audit readiness - applied across your entire portfolio rather than one site at a time.
The result is a coherent activation strategy that lets you sequence sites intelligently, deploy shared SOPs where appropriate, and present the network to sponsors as a single, coordinated capability.
A focused conversation to review your current readiness, discuss your goals, and determine whether Pharmaka is the right fit for the road ahead.